Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
The Motley Fool September 10, 2010 Matt Koppenheffer	How Much Is Wal-Mart Worth? Shares of Wal-Mart currently change hands at roughly $52 per share. Is that a good deal? Let's get an idea of what Wal-Mart's shares are really worth.
The Motley Fool September 3, 2010 Matt Koppenheffer	How Much Is Clorox Worth? Clorox is a stable company with a portfolio of strong brands, opportunity to grow both domestically and internationally, and its stock may be on sale right now.
The Motley Fool August 9, 2010 Matt Koppenheffer	NVIDIA May Be Worth More Than It Seems Is NVIDIA's stock on sale?
The Motley Fool September 2, 2010 Matt Koppenheffer	How Much Is Kimberly-Clark Worth? Is Kimberly-Clark's stock on sale?
The Motley Fool September 16, 2010 Matt Koppenheffer	How Much Is McDonald's Worth? Is McDonald's stock on sale?
The Motley Fool September 30, 2010 Matt Koppenheffer	How Much Is Altria Worth? Is Altria's stock on sale?
The Motley Fool September 24, 2010 Matt Koppenheffer	How Much Is Illinois Tool Works Worth? Is Illinois Tool Work's stock on sale?
The Motley Fool August 31, 2010 Matt Koppenheffer	How Much Is Procter & Gamble Worth? Is Procter & Gamble's stock on sale?
The Motley Fool October 13, 2010 Matt Koppenheffer	How Much Is ADP Worth? Is ADP's stock on sale?
The Motley Fool September 27, 2010 Matt Koppenheffer	How Much Is Nike Worth? Is the shoemaker's stock on sale?
The Motley Fool July 22, 2011 Matt Koppenheffer	Could Eli Lilly's Stock Double Your Money? With concerns swirling around the big pharma companies, could it be time to buy Eli Lilly?
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool October 21, 2010 Brian Orelli	Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool September 10, 2010 Anand Chokkavelu	How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool January 18, 2005 Stephen D. Simpson	Abbott Still Looks Healthy Never a too-big roaring growth stock or a too-small low-growth behemoth, the medical products company seems just right as it dependably keeps on performing for investors.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool June 10, 2011 Matt Koppenheffer	Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio?
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
The Motley Fool October 31, 2011 Matt Koppenheffer	3 Stocks That Other Investors Are Overlooking, but You Shouldn't There are a lot of investors avoiding these three stocks for a very bad reason. Don't fall into the same trap.
The Motley Fool January 18, 2011 Russ Krull	Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold?
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool January 3, 2011 Rex Moore	Highest-Yielding Pharma Stocks (You Might Actually Want to Buy) How to combine high yield with low risk.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool April 1, 2011 Brian Orelli	Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse.